A detailed history of Northern Trust Corp transactions in Werewolf Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 227,750 shares of HOWL stock, worth $357,567. This represents 0.0% of its overall portfolio holdings.

Number of Shares
227,750
Previous 58,598 288.67%
Holding current value
$357,567
Previous $142,000 239.44%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$1.71 - $2.95 $289,249 - $498,998
169,152 Added 288.67%
227,750 $482,000
Q2 2024

Aug 14, 2024

BUY
$2.34 - $6.75 $23,624 - $68,148
10,096 Added 20.82%
58,598 $142,000
Q1 2024

May 14, 2024

SELL
$3.92 - $7.91 $4,492 - $9,064
-1,146 Reduced 2.31%
48,502 $314,000
Q4 2023

Feb 13, 2024

BUY
$1.78 - $4.15 $41,974 - $97,861
23,581 Added 90.46%
49,648 $191,000
Q2 2023

Aug 11, 2023

BUY
$2.31 - $3.65 $14,231 - $22,487
6,161 Added 30.95%
26,067 $79,000
Q1 2023

May 15, 2023

BUY
$1.98 - $4.3 $2,904 - $6,308
1,467 Added 7.96%
19,906 $51,000
Q4 2022

Feb 13, 2023

SELL
$1.53 - $4.73 $174 - $539
-114 Reduced 0.61%
18,439 $37,000
Q3 2022

Nov 14, 2022

BUY
$4.14 - $7.42 $19,602 - $35,133
4,735 Added 34.27%
18,553 $84,000
Q2 2022

Aug 12, 2022

SELL
$3.43 - $5.98 $621,687 - $1.08 Million
-181,250 Reduced 92.92%
13,818 $57,000
Q1 2022

May 13, 2022

SELL
$3.71 - $12.22 $18,538 - $61,063
-4,997 Reduced 2.5%
195,068 $859,000
Q4 2021

Feb 08, 2022

BUY
$11.48 - $17.65 $1.49 Million - $2.29 Million
129,661 Added 184.17%
200,065 $2.38 Million
Q3 2021

Nov 15, 2021

SELL
$13.89 - $20.31 $74,589 - $109,064
-5,370 Reduced 7.09%
70,404 $1.21 Million
Q2 2021

Aug 13, 2021

BUY
$11.6 - $17.44 $878,978 - $1.32 Million
75,774 New
75,774 $1.32 Million

Others Institutions Holding HOWL

About Werewolf Therapeutics, Inc.


  • Ticker HOWL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,529,400
  • Market Cap $46.4M
  • Description
  • Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional ...
More about HOWL
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.